Image
 

Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.

 

 

trial #
trial description
  • Alliance A031102
  • The purpose of this study is to compare the good and bad effects of using standard-doses of chemotherapy to using high-doses of chemotherapy. Both of these types of chemotherapy have been shown to shrink cancer when given as the second chemotherapy treatment, but it is not known whether one type is better than the other. This study will allow researchers to learn whether the high-dose chemotherapy is better, the same, or worse than the standard-dose chemotherapy.

  • CTSU AGCT1531
  • CTSU EA8141
  • CTSU EA8143
  • NRG BR001
  • This study is for patients who have received treatment to the breast, lung or prostate (the first location of cancer) and now the cancer has spread to other parts of the body that have not yet been treated. The purpose of this study is to test the safety of giving a few, focused, high doses of radiation (commonly referred to as stereotactic body radiotherapy [SBRT]) to all known sites of cancer within your body.  

  • NRG GU002
  • The purpose of this study is to compare any good and bad effects of using docetaxel along with the radiation therapy and hormone suppression therapy to using radiation and hormone suppression therapy alone in men with a high chance of prostate cancer recurrence after surgically removing the prostate.  Docetaxel is FDA-approved for prostate cancer that has spread and does not respond to hormone suppression. In this study, docetaxel is being used off-label. Off-label means that the FDA has not yet approved docetaxel for this type of prostate cancer that has not spread. The addition of docetaxel to the usual radiation and hormone suppression therapy could shrink your cancer or prevent it from returning but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.

  • NRG/RTOG 0924
  • The purpose of this study is to compare the effects of hormone therapy and radiation therapy to the prostate gland and seminal vesicles with hormone therapy and radiation therapy to the whole pelvic body area for prostate cancer to find out which is better.

  • NRG/RTOG 0926
  • The purpose of this study is to find out the effects of transurethral surgery followed by radiation therapy plus chemotherapy. Although the combination of radiation therapy and chemotherapy used in this study is not a research treatment because it is used for patients with more advanced bladder cancer (the type that has invaded the bladder muscle), the use of this approach in this study is new for patients with early stage bladder cancer.

  • SWOG S1314
  • The primary focus of this study is to see if looking at tumor biomarkers using a program called “coexpression extrapolation or COXEN” may predict your response to chemotherapy before surgery for bladder cancer.  

  • SWOG S1500
  • The purpose of this study is to compare three experimental drugs not approved by the FDA to treat advanced kidney cancer (crizotinib, cabozantinib and savolitinib) that block a protein called MET to the drug sunitinib which is currently a standard treatment to see if any of these drugs slow down tumor growth compared to sunitinib. Sunitinib is approved by the FDA for treating advanced kidney cancer, but not specifically for treating papillary kidney cancer. This study will allow researchers to know whether any of these drugs are better, the same, or worse than sunitinib. For any of the experimental drugs to be considered better, the experimental drug should increase life by four and a half months or more compared to the drug sunitinib.

  • SWOG S1602
  • SWOG S1605